Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Congenica and Northern Health Science Alliance Announces Partnership

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
Partnership set to accelerate development of diagnostic tools and improve outcomes for patients.

Cambridge based Congenica Ltd and the UK Northern Health Science Alliance have announced a strategic partnership to deliver more accurate diagnostic tools and improve outcomes for patients with genetic conditions.

The aim of the partnership is to accelerate the development of collaborations between Congenica Ltd, a clinical genome diagnostics and discovery company, and that of the leading universities and NHS hospital Trusts in the North of England.

The first proof-of-principle agreement under the partnership has already been formed between Congenica Ltd and Central Manchester University Hospitals NHS Foundation Trust.

The overarching partnership will bring together clinical genetic expertise, molecular diagnostic testing and large-scale genome analytics to develop and implement the next generation sequencing based analysis pipelines, genome-wide interpretation and reporting tools for diagnostic testing. This unique system will be rolled out to a variety of different applications and available through service and licensing business models.

Congenica’s genome analytics platform, which is scalable and capable of processing many thousands of samples per year, is central to the partners’ ambitious plans.

Congenica’s genome analytics platform uses statistical and computational methods, and has the flexibility to evolve with the rapidly changing next generation sequencing technology and clinical applications.

Under the agreement between Congenica and Central Manchester University Hospitals NHS Foundation Trust, the partners will create a reference laboratory. Based at the Manchester Centre for Genomic Medicine, the reference laboratory will undertake genome screening of patients and their unaffected relatives in order to generate a comprehensive genetic profile and clinical report to support diagnosis, the clinical decision making, treatment choice, and counselling.

The partnership will concentrate efforts on developmental disorders, which account for approximately 30% of all genetic disease, but will then follow-on with programs in other therapeutic indications such as ophthalmological, cardiovascular and neurological disease.

“In 2001 the world witnessed the sequencing of the human genome, now in 2014 we are developing tools to help clinicians embed genomic medicine in the clinic. The partnership between Congenica and the Northern Health Science Alliance will further help us understand the utility of genomic medicine and bring the technology one step closer to routine clinical practice”, said Dr Hakim Yadi, Chief Executive of the Northern Health Science Alliance.

“Congenica is extremely pleased to enter into partnership with the NHSA and Central Manchester University Hospitals NHS Foundation Trust. The age of precision medicine is upon us and this is a great opportunity to bring together the wealth of clinical expertise and innovation at Manchester with our scalable genome analytics and clinical decision support tools”, said Dr Tom Weaver, CEO of Congenica. “We strongly believe that partnering is the best way to facilitate rapid adoption of our technology and make a real impact on tackling genetic disease in the clinic.”

Manchester Academic Health Science Centre partners, Central Manchester University Hospitals NHS Foundation Trust and The University of Manchester are renowned for their world-leading clinical and research expertise in genomic medicine. Together, they are founders of the Manchester Centre for Genomic Medicine (MCGM), an integrated academic and service department based at Central Manchester University Hospitals NHS Foundation Trust.

Professor Graeme Black, Strategic Director at the Manchester Centre for Genomic Medicine and Consultant in Genetics and Ophthalmology said: “Manchester was an early adopter of Next Generation Sequencing, and we provide clinical and diagnostic services for inherited disorders to a population of over six million individuals. We bring a wealth of diagnostic and clinical expertise in the diagnosis and management of rare diseases.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Congenica’s Diagnostic Technology Validated by Genomics England
Company selected as one of the winners of a whole genome annotation assessment.
Thursday, October 16, 2014
UK Genomics Medicine Start-up Congenica Ltd Wins Genomics England Competition
Funding to be used by Congenica to further develop it’s SAPIENTIA™ platform.
Tuesday, May 06, 2014
Scientific News
Lung Repair and Regeneration Gene Discovered
New role for hedgehog gene offers better understanding of lung disease.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Finding Links and Missing Genes
A catalogue of large-scale genetic changes around the world.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos